xpress Mail Label:

EV 533192148 US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): TAVERAS, Arthur G.

Group Art Unit: 1626

Application No.: 10/630258

Examiner: Andrew B. Freistein

Atty. Docket No.: OC01406K5

Filed: 07/30/2003

For: 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS

**CXC-CHEMOKINE RECEPTOR LIGANDS** 

Χ

## **INFORMATION DISCLOSURE STATEMENT TRANSMITTAL**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Mail Stop: Sir:

ecord in the patent application National National Nation National	sted on above- ations, o o(s) ave rea	ant to the duty of disclosure under 37 C.F.R. § 1.56, it is requested that the the accompanying Forms PTO/SB/08a & 08b be considered and made of identified patent application. Other than cited U.S. patents and published copy(ies) of these documents are enclosed were filed in related U.S. filed respectively. Since the Examiner is ady access to the cited U.S. patents and published patent applications, ments are not herewith transmitted, but will be provided upon request.
(b)	No fee	e is believed to be due because:
		This Information Disclosure Statement is being submitted concurrently with the filing of the above-identified application; or
		This Information Disclosure Statement is being submitted within three (3) months of the filing date of the above-identified application; <b>or</b>
		This Information Disclosure Statement is being submitted concurrently with a Request for Continued Examination (RCE); or
		This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits.
(c)	×	This Information Disclosure Statement is being submitted before the mailing date of any final action, notice of allowance, or an action that otherwise closes prosecution; and:
		Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

02/27/2006 BABRAHA1 00000011 190365

10630258

01 FC:1806

180.00 DA

Application No. Page 2 of 2

10/630258

				No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; or					
			X	The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.					
	(d)		This Information Disclosure Statement is being submitted on or before payment of the issue fee; and:						
				Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or					
				No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; and					
				The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.					
	The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0365.								
	The submission of these documents is not to be presumed as an admission that these documents are prior art. The documents are being furnished solely for their possible utility in the examination of the present case.								
				Respectfully submitted,					
Scheri Patent 2000 C Kenilw	Depar Sallopir orth, N	ugh Co tment, k ig Hill R J 0703		990 Reg. No.: 30856  Attorney of Record  Telephone No.: 908-298-5041					



for form 1449B/PTO

FEB\_2

EV 533192148 US

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FORMATION DISCLOSURE STATEMENT BY APPLICANT

 Application Number
 10/630258

 Filing Date
 07/30/2003

 First Named Inventor
 TAVERAS, Arthur G.

 Art Unit
 1626

 Examiner Name
 Andrew B. Freistein

Complete if Known

(Use as many sheets as necessary)

Sheet 1 of 1 Attorney Docket Number OC01406K5

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	AA	Communication pursuant to Article 96(2) EPC for Appl. No. 02 739 172.1 - 2101, dated July 13, 2004					
	АВ	Communication pursuant to Article 96(2) EPC for Appl. No. 03 772 075.2 - 2101. dated Nov. 14. 2005					
•••••							
·····		·	• •••••				
	•••••••						
•••••							

Examiner				Date	
Signature				Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.